Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Grant of options

12th Nov 2018 10:33

RNS Number : 0538H
Horizon Discovery Group plc
12 November 2018
 

Horizon Discovery Group plc

12 November 2018

 

 

Horizon Discovery Group plc

 

Cambridge, UK, 12 November 2018: Horizon Discovery Group plc (LSE: HZD) ("Horizon", "the Group" or "the Company"), a global leader in gene editing and gene modulation technologies, announces that the following options were granted over the Company's ordinary shares of 1 pence each ("Ordinary Shares") to its CEO on 9 November 2018 in accordance with the Company's Long Term Incentive Plan:

Director

Number of Ordinary Shares over which options granted

Exercise price per share

Terry Pizzie

325,000

 

£2.00

The options will vest as follows:

· 25% on the third anniversary of the date of grant;

· 25% on the fourth anniversary of the date of grant; and

· 50% on the fifth anniversary of the date of grant.

The options granted are equivalent to 0.22 percent of the Company's existing issued share capital. 

The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

Terry Pizzie

2

Reason for the notification

a)

Position/status

Chief Executive Officer

b)

Initial notification /Amendment

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Horizon Discovery Group plc

b)

Legal Entity Identifier

213800L812B9NI5M3G89

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

 

Identification code

Ordinary shares of 1 pence each

 

 

 

GB00BK8FL363

b)

Nature of the transaction

Grant of share options

c)

Currency

GBP

d)

Price(s) and volume(s)

Price(s)

Volume(s)

N/A

325,000

e)

Aggregated information

- Aggregated volume

- Price

- Aggregated total

 

 

325,000

N/A

N/A 

f)

Date of the transaction

9 November 2018

g)

Place of the transaction

London Stock Exchange, AIM

ENDS

For further information from Horizon Discovery Group plc, please contact:

Horizon Discovery Group plc

Terry Pizzie, Chief Executive Officer

Richard Vellacott, Chief Financial Officer

Tel: +44 (0) 1223 655 580

Numis Securities Limited (Broker and NOMAD)

Michael Meade / Freddie Barnfield

Tel: +44 (0) 207 260 1000

Consilium Strategic Communications (Financial Media and Investor Relations)

Mary-Jane Elliott / Matthew Neal / Melissa Gardiner

Tel: +44 (0) 20 3709 5700

Email: [email protected]

About Horizon Discovery Group plc www.horizondiscovery.com

Horizon Discovery Group plc (LSE: HZD) ("Horizon") is a world leader in gene editing and gene modulation technologies. Horizon designs and engineers cells using its translational genomics platform, a highly precise and flexible suite of DNA editing tools (rAAV, ZFN, CRISPR and Transposon) and, following the acquisition of Dharmacon, Inc., its functional genomics platform comprising gene knockdown (RNAi) and gene expression (cDNA, ORF) tools, for research and clinical applications that advance human health. Horizon's platforms and capabilities enable researchers to alter almost any gene or modulate its function in human or mammalian cell-lines.

Horizon offers an extensive range of catalogue products and related research services to support a greater understanding of the function of genes across all species and the genetic drivers of human disease and the development of personalised molecular, cell and gene therapies. These have been adopted by over 10,000 academic, drug discovery, drug manufacturing and clinical diagnostics customers around the globe, as well as in the Company's own R&D pipeline.

Horizon is headquartered in Cambridge, UK, and is listed on the London Stock Exchange's AIM market under the ticker "HZD".

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
DSHBGBDBIDBBGID

Related Shares:

HZD.L
FTSE 100 Latest
Value8,809.74
Change53.53